iShares Healthcare Innovation UCITS ETF USD (Acc) (GBP) | DRDRRegister to Unlock Ratings |
Performance History | 29/02/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 52.1 | -6.0 | -23.6 | 2.1 | 2.1 | |
+/-Cat | 34.6 | -15.5 | -19.0 | 5.2 | -1.4 | |
+/-B’mrk | - | -24.3 | -29.4 | 4.6 | -3.4 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
Closing Price 27/03/2024 | GBX 608.00 | |
Day Change | 1.19% | |
Morningstar Category™ | Sector Equity Healthcare | |
Volume | 16910 | |
Exchange | LONDON STOCK EXCHANGE, THE | |
ISIN | IE00BYZK4776 | |
Fund Size (Mil) 26/03/2024 | USD 1128.50 | |
Share Class Size (Mil) 26/03/2024 | USD 1128.50 | |
Ongoing Charge 31/01/2023 | 0.40% |
Investment Objective: iShares Healthcare Innovation UCITS ETF USD (Acc) (GBP) | DRDR |
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the STOXX Global Breakthrough Healthcare Index. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
- - | ||
Inception Date 08/09/2016 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
STOXX Global Breakthrough Healthcare | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for iShares Healthcare Innovation UCITS ETF USD (Acc) (GBP) | DRDR | 25/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Neurocrine Biosciences Inc | Healthcare | 2.01 |
UCB SA | Healthcare | 1.82 |
Boston Scientific Corp | Healthcare | 1.77 |
Charles River Laboratories Inter... | Healthcare | 1.76 |
AbbVie Inc | Healthcare | 1.74 |
Increase Decrease New since last portfolio | ||
iShares Healthcare Innovation UCITS ETF USD (Acc) (GBP) | DRDR |